+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Improved bone status by the beta-blocker propranolol in an animal model of nutritional growth retardation

Improved bone status by the beta-blocker propranolol in an animal model of nutritional growth retardation

British Journal of Nutrition 101(11): 1616-1620

The aim of the present research was to study if the beta-blocker propranolol, which is known to increase bone mass, could reverse the adverse skeletal effects of mild chronic food restriction in weanling rats. Male Wistar rats were divided into four groups: control, control+propranolol (CP), nutritional growth retardation (NGR) and nutritional growth retardation+propranolol (NGRP). Control and CP rats were fed freely with the standard diet. NGR and NGRP rats received, for 4 weeks, 80 % of the amount of food consumed by the control and CP rats, respectively. Results were expressed as mean values and sem. Food restriction induced detrimental effects on body and femur weight and length (P < 0.05) and bone structural and geometrical properties (P < 0.001), confirming results previously shown in our laboratory. However, the beta-blocker overcame the deleterious effect of nutritional stress on load-bearing capacity, yielding load, bone stiffness, cross-sectional cortical bone area and second moment of inertia of the cross-section in relation to the horizontal axis without affecting anthropometric, histomorphometric and bone morphometric parameters. The results suggest that propranolol administration to mildly chronically undernourished rats markedly attenuates the impaired bone status in this animal model of growth retardation.

(PDF emailed within 1 workday: $29.90)

Accession: 053743229

Download citation: RISBibTeXText

PMID: 19537307

Related references

Improved bone status by the -blocker propranolol in an animal model of nutritional growth retardation. British Journal of Nutrition 101(11): 1616, 2009

Effects of a non-selective beta-blocker on mandibular bone in an animal model of nutritional growth retardation. Bone 43(6): 0, 2008

mRNA of cytokines in bone marrow and bone biomarkers in response to propranolol in a nutritional growth retardation model. Pharmacological Reports 66(5): 867-873, 2015

Effect of different propranolol doses on skeletal structural and mechanic efficiency in an animal model of growth retardation. Endocrinologia Y Nutricion 59(1): 9-20, 2012

Operational mechanism modification of bone mechanostat in an animal model of nutritional stress: effect of propranolol. Revista de Investigacion Clinica; Organo del Hospital de Enfermedades de la Nutricion 65(1): 39-51, 2013

Effects of the beta-adrenoceptor blocker nipradilol on renal microcirculation in a rat model: A comparative study with propranolol. Current Therapeutic Research 59(3): 179-186, 1998

Comparison of the effects of beta-selectivity and intrinsic sympathomimetic activity in the beta-blocker treatment of dilated cardiomyopathy in an animal model. Circulation 86(4 SUPPL 1): I55, 1992

Growth retardation and nutritional status in foster children. Medicina Clinica 118(3): 86-89, 2002

Zinc nutritional status, androgens, and growth retardation. American Journal of Diseases of Children 135(4): 322-325, 1981

Ask the doctors. I take the beta blocker propranolol twice a day, once in the morning and again in the evening. The drug information label says I should not take propranolol with alcohol. But I like to have two glasses of wine in the evening. Do I need to change medications, or is there a way to handle the wine and propranolol together?. Harvard Heart Letter 24(1): 2-2, 2014

Mechanistic study into the enhanced transdermal permeation of a model beta-blocker, propranolol, by fatty acids: a melting point depression effect. International Journal of Pharmaceutics 219(1-2): 161-176, 2001

Impact of beta-blocker treatment and nutritional status on glycemic response during exercise in patients with type 2 diabetes. Clinical and Investigative Medicine. Medecine Clinique et Experimentale 30(6): E257-E261, 2007

Zinc supplementation in infants with asymmetric intra uterine growth retardation; effect on growth, nutritional status and leptin secretion. Nutricion Hospitalaria 23(3): 212-219, 2008

Energy intake, maternal nutritional status and intrauterine growth retardation. Cadernos de Saude Publica 19(1): 279-285, 2003

Evaluation of nutritional status and pathophysiology of growth retardation in patients with phenylketonuria. Journal of Inherited Metabolic Disease 26(1): 1-11, 2003